Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Fucalpha(1-2)Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Fucalpha(1-2)Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Fucalpha(1-2)Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Fucalpha(1-2)Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
GDP-beta-L-fucose + 3-sulfo-Galbeta1,3GlcNAc
?
GDP-beta-L-fucose + asialofetuin
GDP + ?
-
-
-
-
?
GDP-beta-L-fucose + beta-D-galactosyl-(1->3)-N-acetyl-D-glucosaminyl-R
GDP + beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-R
GDP-beta-L-fucose + beta-D-Galp-(1,3)-beta-D-GlcNAcp-O-(CH2)6-NH-dansyl
GDP + beta-D-Galp-(1,3)[alpha-L-Fuc-(1,4)]-beta-D-GlcNAcp-O-(CH2)6-NH-dansyl
-
-
-
-
?
GDP-beta-L-fucose + fetuin triantennary asialoglycopeptide
?
-
-
-
-
?
GDP-beta-L-fucose + Fucalpha(1->2)Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Fucalpha1,2Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Fucalpha1,2Galbeta1,3GlcNAc
?
GDP-beta-L-fucose + Gal-beta-(1->3)-GlcNAc-beta-O-(CH2)8COOCH3
GDP + Gal-beta-(1->3)-[Fuc-alpha-(1->4)]-GlcNAc-beta-O-(CH2)8COOCH3
-
-
-
?
GDP-beta-L-fucose + Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta-1,3GlcNAc-R
?
-
-
-
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc-O(CH2)8CO2CH3
?
GDP-beta-L-fucose + NeuAcalpha(2,6)Galbeta(1,4)GlcNAc
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha(2->3)Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha(2->3)Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha1-3Galbeta1-3GlcNAc-beta-O-(CH2)8COOCH3
?
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha2-3Galbeta1-4Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
?
-
the enzyme catalyzes the fucose transfer from GDP-fucose to GlcNAc residues of the sialylated polylactosamine acceptor leading to two isomeric monofucosyl antigens, VIM2 and sialyl-Lex
-
-
?
GDP-beta-L-fucose + NeuAcalpha2-3Galbeta1-4Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
GDP + NeuAcalpha2-3Galbeta1-4[Fucalpha1-3]Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
-
the enzyme catalyzes the fucose transfer from GDP-fucose to GlcNAc residues of the sialylated polylactosamine acceptor leading to two isomeric monofucosyl antigens, VIM2 and sialyl-Lex
i.e. sialyl-Lex, main product of FucT-VI, i.e. VIM2, main product of FucT-V
-
?
GDP-beta-L-fucose + Siaalpha-2,3Galbeta-1,3GlcNAc-R
?
-
-
-
?
GDP-beta-L-fucose labelled with ATTO 550 + N-acetyllactosamine labelled with ATTO 647N
?
GDP-D-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
?
-
-
-
-
?
GDP-fucose + 2-aminopyridino-lacto-N-tetraose
GDP + 2-aminopyridino-lacto-N-fucopentaose II
-
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc
GDP + 2-O-MeGal-beta-1,3(Fuc-alpha-1,4)GlcNAc
GDP-fucose + 2-O-MeGal-beta-1,4GlcNAc
GDP + 2-O-MeGal-beta-1,4(Fuc-alpha-1,3)GlcNAc
100% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein
GDP + ?
GDP-fucose + Fetuin triantennary asialo glycoprotein
GDP + ?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-O-C6H5
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-O-C6H5
-
H-type 1 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-O-C6H5
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,3)GlcNAc-O-C6H5
-
H-type 2 reaction, hardly any activity
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
GDP-fucose + Gal-beta-1,3GlcNAc
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc-beta-1,3Gal-beta-1,4Glc
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-beta-1,3Gal-beta-1,4Glc
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc-beta-O-(CH2)7CH3
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-beta-O-(CH2)7CH3
-
type 1 reaction
-
-
?
GDP-Fucose + Gal-beta-1,3GlcNAc-O(CH2)3NHCO(CH2)5NH-biotin
GDP + Gal-beta-1,3[alpha-L-fucosyl-(1,4)]GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc-O-(CH2)3NHCO(CH2)5NH-biotin
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-O-(CH2)3NHCO(CH2)5NH-biotin
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
GDP + Gal-beta-1,3[alpha-L-fucosyl-(1,4)]GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
-
-
-
?
GDP-fucose + Gal-beta-1,4-Glc
GDP + Gal-beta-1,4(Fuc-alpha-1,3)Glc
-
-
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
GDP-fucose + Gal-beta-1,4GlcNAc
GDP + Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc + Gal-beta-1,4(Fuc-alpha-1,2)GlcNAc
-
enzyme activity is divided into 66% alpha-1,3FucT and 34% alpha-1,2FucT
-
-
?
GDP-fucose + Gal-beta-1,4GlcNAc-beta-1-R
GDP + Gal-beta-1,4(fuc-alpha-1,3)GlcNAc-beta-1-R
-
-
-
-
?
GDP-fucose + Gal-beta-1,4GlcNAc-beta-O-(CH2)7CH3
GDP + Gal-beta-1,3(Fuc-alpha-1,3)GlcNAc-beta-O-(CH2)7CH3
-
type 2 reaction, hardly any activity
-
-
?
GDP-fucose + GalNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GalNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
?
acivity not determined
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
GDP + ?
63.8% acivity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
?
acivity not determined
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
GDP + ?
61.5% acivity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GlcNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
GDP-fucose + LacNAc
?
-
-
-
-
?
GDP-L-fucose + (Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
GDP + Fucalpha(1-3)(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
-
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
GDP-L-fucose + 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
GDP + 2-O-MeGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
-
-
-
?
GDP-L-fucose + 3-O-MeGalbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + 3-O-MeGalbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
16.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 17.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,3)GlcNAcbeta(1,3)Galbeta-O-Al
GDP + 3-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta-O-Al
-
64.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 82.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
GDP + 3-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Al
-
64.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 62.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + 3-O-sulfoGalbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
10.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 14.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 6-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
GDP + 6-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Al
-
3.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + alpha(2,3)-sialyllactosamine
GDP + ?
-
56% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + alpha-(2,3)-sialylated Galbeta(1,3)GlcNAc
GDP + ?
-
-
-
-
?
GDP-L-fucose + ancrod
GDP + ?
-
-
-
-
?
GDP-L-fucose + asialo ancrod
GDP + ?
-
-
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
GDP-L-fucose + fetuin triantennary glycopeptide
GDP + ?
-
-
-
-
?
GDP-L-fucose + formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
GDP + ?
-
-
-
-
?
GDP-L-fucose + Fuc-alpha1-2Galbeta1-4GlcNAc-octyl
GDP + ?
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + ?
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)5-NH-biotin
-
193% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-O-sp-biotin
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-O-sp-biotin
-
118% of the activity with Galbeta3GlcNAc-O-sp-biotin
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-R
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))Glc
-
34.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 38.7% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
3% of the activity with with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin, enzyme expressed in Sf9 cells
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)5-NH-biotin
-
9.3% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-O-sp-biotin
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-O-sp-biotin
-
10.5% of the activity with Galbeta3GlcNAc-O-sp-biotin
-
-
?
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAc-R
GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAcbeta-O-Naph
GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Naph
-
42.6 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 46.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,3)(6-O-sulfo)GlcNAcbeta(1,3)Galbeta-O-Al
GDP + ?
-
15.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 19.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
GDP-L-fucose + Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc-O-sp-biotin
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-O-sp-biotin
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc-R
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
20% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta-O-Bn
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
79.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 83.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)-(5-thioGlc)
GDP + ?
-
51% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
GDP-L-fucose + Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
2% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin, enzyme expressed in Sf9 cells
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
33% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(3-O-MeGalbeta(1,3))GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(3-O-MeGalbeta(1,3))GalNAcalpha-O-Bn
-
2.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(3-O-sulfoGalbeta(1,3))-GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(3-O-sulfoGalbeta(1,3))-GalNAcalpha-O-Bn
-
1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
2.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta-O-Bn
-
3.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 2.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbetaOallyl
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl
-
64% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)Glucal
GDP + Galbeta(1,4)(Fucalpha(1,3))Glucal
-
10% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,6)Galbeta(1,4)Glc
GDP + ?
-
-
-
-
?
GDP-L-fucose + Galbeta(1-3)GlcNAcbeta-O-Me
GDP + Fucalpha(1-3)Galbeta(1-3)GlcNAcbeta-O-Me
-
-
-
-
?
GDP-L-fucose + Galbeta1-4GlcNAc-4-nitrophenyl
GDP + ?
-
-
-
-
?
GDP-L-fucose + GalNAcbeta(1,3)(6-O-sulfo)GlcNAcbeta-O-Me
GDP + ?
-
6.2 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 8.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + GalNAcbeta1-4GlcNAc-diaminopimelyl
GDP + ?
-
-
-
-
?
GDP-L-fucose + GalNAcbeta1-4GlcNAc-octyl
GDP + ?
-
shows the highest catalytic activity as an acceptor substrate
-
-
?
GDP-L-fucose + IL-4 receptor
GDP + ?
-
-
-
-
?
GDP-L-fucose + lacto-N-neotetraose
GDP + ?
-
-
-
-
?
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
GDP + N-[(1R,3R,5R,6S,7S,8R,13R,15R,16R,17S)-6,17-dihydroxy-5-hydroxymethyl-15-methoxy-7-((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl]-acetamide
-
low activity with FucT IV and FucT VI
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
GDP + N-[(1R,3R,5R,6S,7S,8R,13R,15R,16R,17S)-6,17-dihydroxy-5-hydroxymethyl-15-methoxy-7-((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl]-acetamide
-
-
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
GDP + ?
-
-
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
GDP + ?
-
-
-
-
?
GDP-L-fucose + N-acetyllactosamine
GDP + alpha-1,3-L-fucosyl-N-acetyllactosamine
-
-
-
-
?
GDP-L-fucose + NeuAc(2,3)Galbeta(1,4)Glucal
GDP + NeuAc(2,3)Galbeta(1,4)(Fucalpha(1,3))Glucal
-
330% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAc(2,6)Galbeta(1,4)GlcNAc
GDP + NeuAc(2,6)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
13% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAc-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)5-NH-biotin
-
57% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
55.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 64.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
620% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
24.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 12.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta-O-Bn
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta-O-Bn
-
6.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 7.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbetaOallyl
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl
-
380% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)AspNHCO-biotin + GDP
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
NeuAcalpha(2-3)Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
NeuAcalpha(2-3)Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
pyridylamine-lacto-N-neotetraose + GDP-fucose
GDP + ?
-
-
-
-
?
additional information
?
-
GDP-beta-L-fucose + 3-sulfo-Galbeta1,3GlcNAc
?
-
40% of the activity with Galbeta1,3GlcNAc
-
-
?
GDP-beta-L-fucose + 3-sulfo-Galbeta1,3GlcNAc
?
-
40% of the activity with Galbeta1,3GlcNAc
-
-
?
GDP-beta-L-fucose + 3-sulfo-Galbeta1,3GlcNAc
?
-
40% of the activity with Galbeta1,3GlcNAc
-
-
?
GDP-beta-L-fucose + beta-D-galactosyl-(1->3)-N-acetyl-D-glucosaminyl-R
GDP + beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-R
-
isoform Fut3 predominantly exhibits alpha1-4 fucosyltransferase activity
-
-
?
GDP-beta-L-fucose + beta-D-galactosyl-(1->3)-N-acetyl-D-glucosaminyl-R
GDP + beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-R
-
-
-
-
?
GDP-beta-L-fucose + Fucalpha1,2Galbeta1,3GlcNAc
?
-
34% of the activity with Galbeta1,3GlcNAc
-
-
?
GDP-beta-L-fucose + Fucalpha1,2Galbeta1,3GlcNAc
?
-
34% of the activity with Galbeta1,3GlcNAc
-
-
?
GDP-beta-L-fucose + Fucalpha1,2Galbeta1,3GlcNAc
?
-
34% of the activity with Galbeta1,3GlcNAc
-
-
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc-O(CH2)8CO2CH3
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc-O(CH2)8CO2CH3
?
-
-
-
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc-O(CH2)8CO2CH3
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta1,3GlcNAc-O(CH2)8CO2CH3
?
-
-
-
-
?
GDP-beta-L-fucose labelled with ATTO 550 + N-acetyllactosamine labelled with ATTO 647N
?
-
-
-
-
?
GDP-beta-L-fucose labelled with ATTO 550 + N-acetyllactosamine labelled with ATTO 647N
?
-
-
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc
GDP + 2-O-MeGal-beta-1,3(Fuc-alpha-1,4)GlcNAc
17.6% activity
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc
GDP + 2-O-MeGal-beta-1,3(Fuc-alpha-1,4)GlcNAc
19.4% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein
GDP + ?
42.9% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein
GDP + ?
5.2% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo glycoprotein
GDP + ?
36.9% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo glycoprotein
GDP + ?
73.8% activity
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin
type 1 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin
type 1 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin
type 1 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin
type 1 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin
type 2 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin
type 2 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin
type 2 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin
type 2 reaction
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT 11639(347CNDAHYSALH)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT UA948(1-360)11639(360-478)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT UA948(345DNPFIFC)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, strain UA948
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT 11639(347CNDAHYSALH)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT UA948(1-360)11639(360-478)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT UA948(345DNPFIFC)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, strain UA948
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT 11639(347CNDAHYSALH)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT UA948(1-360)11639(360-478)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, chimeric FucT UA948(345DNPFIFC)
-
-
?
GDP-fucose + Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,3[alpha-fucosyl(1,4)]-GLCNAc-O-(CH2)8CO2CH3
type 1 reaction, strain UA948
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
type 2 reaction, chimeric FucT 11639(1-359)UA948(361-462)
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
type 2 reaction, chimeric FucT 11639(347CNDAHYSALH)
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
type 2 reaction, chimeric FucT UA948(1-360)11639(360-478)
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
type 2 reaction, chimeric FucT UA948(345DNPFIFC)
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
type 2 reaction, strain NCTC116639
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
type 2 reaction, strain UA948
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
type 2 reaction, chimeric FucT 11639(1-359)UA948(361-462)
-
-
?
GDP-fucose + Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
GDP + Gal-beta-1,4[alpha-fucosyl(1,3)]-GLCNAc-O-(CH2)8CO2CH3
type 2 reaction, chimeric FucT 11639(1-359)UA948(361-462)
-
-
?
GDP-fucose + GalNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GalNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
91.9% activity
-
-
?
GDP-fucose + GalNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GalNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
95.0% activity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GlcNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
11.3% activity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GlcNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
89.1% activity
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
inactivation of the enzyme eliminates expression of all Lewis antigens
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
inactivation of the enzyme eliminates expression of all Lewis antigens
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme catalyzes the synthesis of fucosylated Lewis motifs that are associated with cell-adhesion events and are differentially expressed during cell differentiation
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha-1,3 and alpha-1,4 glycosidic linkages involved in expression of sialyl Lewis X and Lewis X/SSEA-1 antigens. It may be involved in blood group Lewis determination
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme appears to add fucose with a greater than 5fold preference for type II chains but still retains significant activity using type I acceptors. The addition of fucose to type II acceptors does not appear to be affected by fucosylation at other sites on the carbohydrate acceptor
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme appears to add fucose with a greater than 5fold preference for type II chains but still retains significant activity using type I acceptors. The addition of fucose to type II acceptors does not appear to be affected by fucosylation at other sites on the carbohydrate acceptor
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
-
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme has a clear preference for the Galbeta3GlcNAc motif in oligosaccharides conjugated with the hydrophobic tail (CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
transfer of fucose to N-acetylglucosamine in the type I Galbeta3GlcNAc motif from oligosaccharides linked to a hydrophobic tail and glycoproteins containing the type I motif. Sialylated oligosaccharides containing the type II Galbeta4GlcNAc motif are not acceptors
-
?
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
-
-
-
-
?
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
-
254% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
-
11% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
-
-
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
-
no activity
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
-
the acceptor oligosaccharide in bovine asialofetuin is the man3 branched triantennary isomer with one Galbeta(1,3)GlcNAc
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
-
7.3% of the activity with Galbeta3GlcNAc-O-sp-biotin
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
activity of the wild-type enzyme is about 3% of the activity with Fucalpha(1,2)Galbeta(1,4)GlcNAc. The mutation W111R shows higher activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc than for Fucalpha(1,2)Galbeta(1,4)GlcNAc. The addition mutation in W11R/D112E increases activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc compared to mutant W111R
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-R
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-R
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
i.e. lacto-N-fucopentaose I
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
mutant enzyme D336A shows 40fold reduction in activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
-
?
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAc-R
GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAc-R
GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
130% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
29% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
420% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
45.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 51% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc-R
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc-R
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
-
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
145% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
i.e. lactose, 2% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
i.e. N-acetyllactosamine
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
3.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
43% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
-
-
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
-
28% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
-
on the cell surface of hepatocarcinoma cells H7721
-
-
?
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
-
the enzyme, especially subtype FucT VI, is responsible for alpha-1,3-fucosylation in the synthesis of Lewis antigens Lex, SLex, and SDLex on the cell surface consist of sialylated or nonsialylated N-acetyllactosamine located on the outer chains of the glycan moieties of glycolipids or the O-linked glycans of glycoproteins, the isozymes prefer sialylated, alphaFucT III, V, VI, and VII, or nonsialylated, alphaFucT IV and IX, N-acetyllactosamine
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
FUT10 activity toward the acceptor 0989-BM is increased by about 50% compared with those observed using BGA-biotin
-
-
?
additional information
?
-
-
the enzyme shows alpha1,3- and alpha1,4-fucosyltransferase activity
-
-
?
additional information
?
-
-
the enzyme shows alpha1,3- and alpha1,4-fucosyltransferase activity
-
-
?
additional information
?
-
-
the enzyme shows alpha1,3- and alpha1,4-fucosyltransferase activity
-
-
?
additional information
?
-
-
11 nonidentical amino acids, found within a hypervariable peptide segment positioned at the NH2 terminus determins whether or not a alpha(1,3)-fucosyltransferase can utilize type I acceptor substrates to form Lewis a and sialyl Lewis a moieties
-
-
?
additional information
?
-
-
activity with type 2 substrates is 1% or less than the activity with type 1 substrates
-
-
?
additional information
?
-
-
high substrate affinity for clustered units of 3-sialyl Galbeta(1,3)GlcNAcbeta in asparagine linked carbohydrate as well as for mucin core 2 structure containing 3-sialyl Galbeta1,4GlcNAcbeta-unit, in addition of alpha(1,2)-L-fucosylating activity
-
-
?
additional information
?
-
-
the enzyme transferrs fucose to the O-4-position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides and glycoproteins containing the type I Galbeta(1,3)GlcNAc motif
-
-
?
additional information
?
-
the enzyme is involved in the biosynthesis of the E-selectin ligand, sialyl-Lewis X. Catalyzes the transfer of fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates
-
-
?
additional information
?
-
-
the enzyme is involved in the biosynthesis of the E-selectin ligand, sialyl-Lewis X. Catalyzes the transfer of fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates
-
-
?
additional information
?
-
-
the enzyme is involved in the biosynthesis of the sialyl Lewis x, i.e. Lex, epitope on leukocytes, which has been identified as an important component of leukocyte ligands for E- and P-selectin
-
-
?
additional information
?
-
-
no activity with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-beta-1,3Gal-beta-1,4Glc, Fuc-alpha-1,2Gal-beta-1,4Glc, and NeuAc-alpha-2,3-Gal-beta-1,4GlcNAc
-
-
?
additional information
?
-
-
substrate specificity of FucT IV and FucT VI with N-acetyllactosamine derivatives, determination of the required conformational properties of oligosaccharide acceptors
-
-
?
additional information
?
-
-
the strong correlation between the promoter activity of the FUT III gene and the high expression of sialyl Le(a) observed in different colon carcinoma cell lines seems to conform the important regulatory role of FUT3 in the synthesis of sialyl Le(a)
-
-
?
additional information
?
-
-
FucT-III and FucT-V catalyze fucose transfer to Galbeta1-3GlcNAc chain acceptors in an alpha1,4-linkage, these two enzymes have distinct site-specific fucosylation properties, site-specific fucosylation is defined within a 40-amino acid segment containing 8 amino acid differences between the two enzymes, FucT-VI has about 12fold higher activity compared with FucT-V with the Trp124/Arg110 site in the enzymes being responsible primarily for this activity difference, substrate specificities of wild-type and mutant enzymes, overview
-
-
?
additional information
?
-
-
FucT-III catalyzes the transfer of fucose onto position-4 or position-3 of the N-acetylglucosamine unit of disaccharides beta-D-Galp-(1,3)-beta-D-GlcpNAc or beta-D-Galp-(1,4)-beta-D-GlcpNAc, respectively. FucT-III is an inverting enzyme
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galb1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galb1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galbeta1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galbeta1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
-
FUT6 can synthesize sialyl Lewis x in KATO III cells whereas FUT5 is most likely responsible for the synthesis of this epitope in HT29 and MKN45 cells. FUT3 and to a lower extent FUT5 have the capability to synthesize sialyl Lewis a
-
-
?
additional information
?
-
-
the enzyme transfers fucose from the GDP-fucose donor onto different glycoconjugate acceptors, such as, glycoproteins, glycolipids and oligosaccharides. Isoforms FUT3 to FUT7 and FUT9 to FUT11 belong to the group of alpha1,3/4-fucosyltransferases. FUT3 predominantly exhibits alpha1,4-fucosyltransferase activity synthesizing Lewis a, NeuAcalpha2,3Galbeta(1->3)[Fucalpha(1->4)]GlcNAc-R and Lewis b, and a minor alpha1,3-FUT activity, synthesizing Lewis x, sialyl Lewis x and Lewis y. FUT5 and FUT6 synthesize Lewis x and NeuAcalpha2,3Galbeta(1->4)[Fucalpha(1->3)]GlcNAc-R. FUT7 is an alpha1,3-FUT that synthesizes only sialyl Lewis x. FUT4 and FUT9 produce Lewis x and Lewis y. FUT10 and FUt11 exhibit alpha1,3-fucosyltransferase activity
-
-
?
additional information
?
-
-
activity with type 2 substrates is 1% or less than the activity with type 1 substrates
-
-
?
additional information
?
-
no substrate: 2-aminopyridino-lacto-N-neotetraose
-
-
-
additional information
?
-
no substrate: 2-aminopyridino-lacto-N-neotetraose
-
-
-
additional information
?
-
-
isoform FUT7 is able to synthesize both di- and tri-fucosylated structures from monofucosylated precursors but preferentially fucosylates the distal N-acetylglucosamine within a polylactosamine chain
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.12 - 2.7
(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
0.16 - 0.4
2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
0.047 - 0.1
3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
0.045
ancrod
-
enzyme form FTB
-
0.167
asialo ancrod
-
enzyme form FTB
-
0.63
fetuin triantennary asialoglycopeptide
-
enzyme form FTB
-
1.43
fetuin triantennary glycopeptide
-
enzyme form FTB
-
0.075 - 1.3
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
0.2 - 2.5
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.1 - 1.3
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.14
Fuc-alpha1-2Galbeta1-4GlcNAc-octyl
-
-
0.1 - 3.8
Fucalpha(1,2)Galbeta(1,3)GlcNAc
0.8
Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
1.52
Fucalpha(1,2)Galbeta(1,4)Glc
-
enzyme form FTB
0.5 - 0.7
Fucalpha(1,2)Galbeta(1,4)GlcNAc
8.4 - 22.7
Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
0.7 - 3.3
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
0.17 - 2.2
Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
0.6 - 12.7
Galbeta(1,3)GlcNAc
0.76 - 0.87
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
2.4
Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
0.012
Galbeta(1,4)(5-thioGlc)
-
-
0.035 - 8.1
Galbeta(1,4)GlcNAc
0.4
Galbeta(1,4)GlcNAcbeta(1,2)Man
-
-
3.8
Galbeta(1,4)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
0.016
Galbeta(1,4)GlcNAcbetaOallyl
-
-
0.034
Galbeta(1,4)Glucal
-
-
12
Galbeta(1,6)Galbeta(1,4)Glc
-
-
0.35 - 1.2
Galbeta(1-3)GlcNAcbeta-O-Me
0.114
Galbeta-1,3GlcNAc-R
37°C, pH 6.5
5.7 - 13.3
Galbeta1,3GlcNAc-O(CH2)8CO2CH3
3.6
Galbeta1-4GlcNAc-4-nitrophenyl
-
-
3.8
GalNAcbeta1-4GlcNAc-diaminopimelyl
-
-
0.27
GalNAcbeta1-4GlcNAc-octyl
-
-
0.00573 - 0.0337
GDP-beta-L-fucose
0.1145
GDP-D-fucose
-
mutant enzyme D336A
0.005 - 0.035
GDP-L-fucose
0.15 - 0.154
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
3 - 25
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
1.1 - 11
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
0.61 - 16
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
0.4 - 5
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
0.67 - 2.5
NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
0.1 - 0.28
NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
0.77 - 3.3
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
0.064
NeuAcalpha(2,3)Galbeta(1,4)Glucal
-
-
0.07
NeuAcalpha(2,6)Galbeta(1,4)GlcNAc
-
-
0.111
Siaalpha-2,3Galbeta-1,3GlcNAc-R
37°C, pH 6.5
0.12
(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
pH 6.5, 37°C, recombinant FucT VI
2.7
(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
pH 6.5, 37°C, recombinant FucT IV
0.16
2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
-
enzyme form FTB
0.4
2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
-
enzyme form FTA
0.047
3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
-
enzyme form FTB
0.1
3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
-
enzyme form FTA
0.075
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
-
pH 6.5, 37°C, recombinant FucT VI
1.3
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
-
pH 6.5, 37°C, recombinant FucT IV
0.2
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
wildtype
0.3
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111F
0.3
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111Y
2.5
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111A
0.1
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
mutant W124R
1.1
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
wildtype
1.3
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
mutant W124Y
0.1
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
-
0.2
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
wild-type enzyme
0.4
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
mutant enzyme D112E
2
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
mutant enzyme W111R/D112E
3.8
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
fucosyltransferase III mutant enzyme D336A
0.5
Fucalpha(1,2)Galbeta(1,4)GlcNAc
-
mutant enzyme W111R/D112E
0.7
Fucalpha(1,2)Galbeta(1,4)GlcNAc
-
mutant enzyme W111R
8.4
Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
strain UA948
9.7
Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
chimeric FucT UA948(1-360)11639(360-478)
20.8
Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
chimeric FucT 11639(347CNDAHYSALH)
22.7
Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3
chimeric FucT UA948(345DNPFIFC)
0.7
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 7.0 and presence of Mn2+
0.9
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 4.7 and absence of Mn2+
1.5
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 4.7 and presence of Mn2+
3.3
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 7.0 and absence of Mn2+
0.17
Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
chimeric FucT UA948(345DNPFIFC)
0.31
Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
wild type, strain NCTC116639
0.7
Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
chimeric FucT 11639(1-359)UA948(361-462)
1.2
Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
strain UA948
1.3
Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
chimeric FucT UA948(1-360)11639(360-478)
2.2
Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3
chimeric FucT 11639(347CNDAHYSALH)
0.6
Galbeta(1,3)GlcNAc
-
-
1.9
Galbeta(1,3)GlcNAc
-
-
12.7
Galbeta(1,3)GlcNAc
-
-
0.76
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
enzyme expressed n Sf9 cells
0.87
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
enzyme expressed in Trichoplusia ni
0.035
Galbeta(1,4)GlcNAc
-
-
1.6
Galbeta(1,4)GlcNAc
-
-
8.1
Galbeta(1,4)GlcNAc
-
-
0.35
Galbeta(1-3)GlcNAcbeta-O-Me
-
pH 6.5, 37°C, recombinant FucT VI
1.2
Galbeta(1-3)GlcNAcbeta-O-Me
-
pH 6.5, 37°C, recombinant FucT IV
5.7
Galbeta1,3GlcNAc-O(CH2)8CO2CH3
-
truncated enzyme UA948(1-428)
13.3
Galbeta1,3GlcNAc-O(CH2)8CO2CH3
-
full-length enzyme
0.00573
GDP-beta-L-fucose
37°C, pH 6.5
0.0119
GDP-beta-L-fucose
-
cosubstrate: Galbeta1,3GlcNAc-O(CH2)8CO2CH3, truncated enzyme UA948(1-428)
0.0337
GDP-beta-L-fucose
-
cosubstrate: Galbeta1,3GlcNAc-O(CH2)8CO2CH3, full-length enzyme
0.03
GDP-fucose
mutant W124R, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.034
GDP-fucose
mutant W111Y, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.035
GDP-fucose
mutant W124Y, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.035
GDP-fucose
wildtype, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.0357
GDP-fucose
with Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3, strain UA948
0.037
GDP-fucose
mutant W111F, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.038
GDP-fucose
wildtype, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.046
GDP-fucose
mutant W111A, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.048
GDP-fucose
with Gal-beta-1,4beta-GlcNAc-O-(CH2)8CO2CH3, wild type, strain NCTC116639
0.0481
GDP-fucose
with Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3, chimeric FucT UA948(345DNPFIFC)
0.0546
GDP-fucose
with Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3, chimeric FucT 11639(347CNDAHYSALH)
0.0683
GDP-fucose
with Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3, strain UA948
0.153
GDP-fucose
with beta-Gal1,4-GlcNAc-O-(CH2)8CO2CH3, chimeric FucT 11639(1-359)UA948(361-462)
0.188
GDP-fucose
with Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3, chimeric FucT UA948(1-360)11639(360-478)
0.213
GDP-fucose
with Gal-beta-1,3-GlcNAc-O-(CH2)8CO2CH3, chimeric FucT UA948(345DNPFIFC)
0.236
GDP-fucose
with Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3, chimeric FucT UA948(1-360)11639(360-478)
0.244
GDP-fucose
with Gal-beta-1,4-GlcNAc-O-(CH2)8CO2CH3, chimeric FucT 11639(347CNDAHYSALH)
0.005
GDP-L-fucose
-
reaction with Galbeta(1,4)GlcNAc
0.0105
GDP-L-fucose
-
reaction with Galbeta(1,3)GlcNAc
0.013
GDP-L-fucose
FUT10-391
0.0131
GDP-L-fucose
-
reaction with lactose
0.015
GDP-L-fucose
FUT10-479
0.03
GDP-L-fucose
-
mutant enzyme W111R
0.032
GDP-L-fucose
-
mutant enzyme W111R/D112E
0.033
GDP-L-fucose
-
mutant enzyme D112E
0.0336
GDP-L-fucose
-
fucosyltransferase III
0.035
GDP-L-fucose
-
wild-type enzyme
0.15
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
FUT10-479
0.154
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
FUT10-391
3
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
25
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
1.1
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
11
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.61
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
16
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.4
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
5
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.67
NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
-
enzyme form FTB
2.5
NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
-
enzyme form FTA
0.1
NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
-
-
0.28
NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
-
-
0.77
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
enzyme form FTB
3.3
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
enzyme form FTB
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Karaivanova, V.; Mookerjea, S.; Hunt, D.; Nagpurkar, A.
Characterization and purification of fucosyltransferases from the cytosol of rat colon
Int. J. Biochem. Cell Biol.
28
165-174
1996
Rattus norvegicus
brenda
Wong, C.H.; Dumas, D.P.; Ichikawa, Y.; Koseki, K.; Danishefsky, S.J.; Weston, B.W.; Lowe, J.B.
Specificity, inhibition, and synthetic utility of a recombinant human alpha-1,3-fucosyltransferase
J. Am. Chem. Soc.
114
7321-7322
1992
Homo sapiens
-
brenda
Prieels, J.P.; Monnom, D.; Dolmans, M.; Beyer, T.A.; Hill, R.L.
Co-purification of the Lewis blood group N-acetylglucosaminide alpha 1-4 fucosyltransferase and an N-acetylglucosaminide alpha 1-3 fucosyltransferase from human milk
J. Biol. Chem.
256
10456-10463
1981
Homo sapiens
brenda
Palma, A.S.; Vila-Verde, C.; Pires, A.S.; Fevereiro, P.S.; Costa, J.
A novel plant alpha4-fucosyltransferase (Vaccinium myrtillus L.) synthesises the Lewisa adhesion determinant
FEBS Lett.
499
235-238
2001
Homo sapiens, Vaccinium myrtillus
brenda
Sousa, V.L.; Costa, M.T.; Palma, A.S.; Enguita, F.; Costa, J.
Localization, purification and specificity of the full-length membrane-bound form of human recombinant alpha 1,3/4-fucosyltransferase from BHK-21B cells
Biochem. J.
357
803-810
2001
Homo sapiens
brenda
Rasko, D.A.; Wang, G.; Palcic, M.M.; Taylor, D.E.
Cloning and characterization of the alpha(1,3/4) fucosyltransferase of Helicobacter pylori
J. Biol. Chem.
275
4988-4994
2000
Helicobacter pylori (O32631), Helicobacter pylori, Helicobacter pylori UA948 (O32631)
brenda
Legault, D.J.; Kelly, R.J.; Natsuka, Y.; Lowe, J.B.
Human alpha(1,3/1,4)-fucosyltransferases discriminate between different oligosaccharide acceptor substrates through a discrete peptide fragment
J. Biol. Chem.
270
20987-20996
1995
Homo sapiens
brenda
Holmes, E.H.; Yen, T.Y.; Thomas, S.; Joshi, R.; Nguyen, A.; Long, T.; Gallet, F.; Maftah, A.; Julien, R.; Macher, B.A.
Human alpha1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites
J. Biol. Chem.
275
24237-24245
2000
Homo sapiens
brenda
Dupuy, F.; Germot, A.; Marenda, M.; Oriol, R.; Blancher, A.; Julien, R.; Maftah, A.
alpha1,4-Fucosyltransferase activity: a significant function in the primate lineage has appeared twice independently
Mol. Biol. Evol.
19
815-824
2002
Homo sapiens, Macaca mulatta
brenda
Morais, V.A.; Serpa, J.; Palma, A.S.; Costa, T.; Maranga, L.; Costa, J.
Expression and characterization of recombinant human alpha-3/4-fucosyltransferase III from Spodoptera frugiperda (Sf9) and Trichoplusia ni (Tn) cells using the baculovirus expression system
Biochem. J.
353
719-725
2001
Homo sapiens
brenda
Weston, B.W.; Nair, R.P.; Larsen, R.D.; Lowe, J.B.
Isolation of a novel human alpha (1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha (1,3/1,4)fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specificities
J. Biol. Chem.
267
4152-4160
1992
Homo sapiens
brenda
Vo, L.; Lee, S.; Marcinko, M.C.; Holmes, E.H.; Macher, B.A.
Human alpha1,3/4-fucosyltransferases II. A single amino acid at the COOH terminus of FucT III and V alters their kinetic properties
J. Biol. Chem.
273
25250-25255
1998
Homo sapiens
brenda
Dupuy, F.; Petit, J.M.; Mollicone, R.; Oriol, R.; Julien, R.; Maftah, A.
A single amino acid in the hypervariable stem domain of vertebrate alpha1,3/1,4-fucosyltransferases determines the type 1/type 2 transfer. Characterization of acceptor substrate specificity of the Lewis enzyme by site-directed mutagenesis
J. Biol. Chem.
274
12257-12262
1999
Homo sapiens
brenda
Chandrasekaran, E.V.; Chawda, R.; Rhodes, J.M.; Xia, J.; Piskorz, C.; Matta, K.L.
Human lung adenocarcinoma alpha1,3/4-L-fucosyltransferase displays two molecular forms, high substrate affinity for clustered sialyl LacNAc type 1 units as well as mucin core 2 sialyl LacNAc type 2 unit and novel alpha1,2-L-fucosylating activity
Glycobiology
11
353-363
2001
Homo sapiens
brenda
Costa, J.; Grabenhorst, E.; Nimtz, M.; Conradt, H.S.
Stable expression of the Golgi form and secretory variants of human fucosyltransferase III from BHK-21 cells. Purification and characterization of an engineered truncated form from the culture medium
J. Biol. Chem.
272
11613-11621
1997
Homo sapiens
brenda
Costache, M.; Apoil, P.A.; Cailleau, A.; Elmgren, A.; Larson, G.; Henry, S.; Blancher, A.; Iordachescu, D.; Oriol, R.; Mollicone, R.
Evolution of fucosyltransferase genes in vertebrates
J. Biol. Chem.
272
29721-29728
1997
Pan troglodytes (O19058)
brenda
Oulmouden, A.; Wierinckx, A.; Petiti, J.M.; Costache, M.; Palcic, M.M.; Mollicone, R.; Oriol, R.; Julien, R.
Molecular cloning and expression of a bovine alpha(1,3)-fucosyl gene homologous to a putative ancestor gene of the human FUT-3-FUT5-FUT6 cluster
J. Biol. Chem.
272
8764-8773
1997
Bos taurus (Q11126)
brenda
Kukowska-Latallo, J.F.; Larsen, R.D.; Nair, R.P.; Lowe, J.B.
A cloned human cDNA determines expression of mouse stage-specific embryonic antigen and the Lewis blood group alpha(1,3/1,4)fucosyltransferase
Genes Dev.
4
1288-1303
1990
Homo sapiens (P21217)
brenda
Cameron, H.S.; Szczepaniak, D.; Weston, B.W.
Expression of human chromosome 19p alpha(1,3)-fucosyltransferase genes in normal tissues. Alternative splicing, polyadenylation, and isoforms
J. Biol. Chem.
270
20112-20122
1995
Homo sapiens (P21217)
brenda
Elmgren, A.; Rydberg, L.; Larson, G.
Genotypic heterogeneity among Lewis negative individuals
Biochem. Biophys. Res. Commun.
196
515-520
1993
Homo sapiens (P21217)
brenda
Nishihara, S.; Yazawa, S.; Iwasaki, H.; Nakazato, M.; Kudo, T.; Ando, T.; Narimatsu, H.
alpha(1,3/1,4)fucosyltransferase (FucT-III) gene is inactivated by a single amino acid substitution in Lewis histo-blood type negative individuals
Biochem. Biophys. Res. Commun.
196
624-631
1993
Homo sapiens (P21217), Homo sapiens
brenda
Koda, Y.; Kimura, H.; Mekada, E.
Analysis of Lewis fucosyltransferase genes from the human gastric mucosa of Lewis-positive and -negative individuals
Blood
82
2915-2919
1993
Homo sapiens (P21217)
brenda
Mollicone, R.; Reguigne, I.; kelly, R.J.; Fletcher, A.; Watt, J.; Chatfield, S.; Aziz, A.; Cameron, H.S.; Weston, B.W.; Lowe, J.B.; Oriol, R.
Molecular basis for Lewis alpha(1,3/1,4)-fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian pedigrees
J. Biol. Chem.
269
20987-20994
1994
Homo sapiens (P21217)
brenda
Nishihara, S.; Narimatsu, H.; Iwasaki, H.; Yazawa, S.; Akamatsu, S.; Ando, T.; Sena, T.; Narimatsu, I.
Molecular genetic analysis of the human Lewis histo-blood group system
J. Biol. Chem.
269
29271-29278
1994
Homo sapiens (P21217), Homo sapiens
brenda
Elmgren, A.; Boerjeson, C.; Svensson, L.; Rydberg, L.; Larson, G.
DNA sequencing and screening for point mutations in the human Lewis FUT gene enables molecular genotyping of the human Lewis blood group system
Vox Sang.
70
97-103
1996
Homo sapiens (P21217)
brenda
Elmgren, A.; Mollicone, R.; Costache, M.; Boerjeson, C.; Oriol, R.; Harrington, J.; Larson, G.
Significance of individual point mutations, T202C and C314T in the human Lewis FTA3' gene for expression of Lewis antigens by human alpha1,3/1,4'-fucosyltransferase, Fuc-TIII
J. Biol. Chem.
272
21994-21998
1997
Homo sapiens (P21217), Homo sapiens
brenda
Pang, H.; Liu, Y.; Koda, Y.; Soejima, M.; Jia, J.; Schlaphoff, T.; du Toit, E.D.; Kimura, H.
Five novel missense mutations of the Lewis gene FUT3' in African Xhosa and Caucasian populations in South Africa
Hum. Genet.
102
675-680
1998
Homo sapiens (P21217)
brenda
Koszdin, K.L.; Bowen, B.R.
The cloning and expression of a human alpha-1,3 fucosyltransferase capable of forming the E-selectin ligand
Biochem. Biophys. Res. Commun.
187
152-157
1992
Homo sapiens (P51993), Homo sapiens
brenda
Galan, M.C.; Venot, A.P.; Boons, G.J.
Glycosyltransferase activity can be modulated by small conformational changes of acceptor substrates
Biochemistry
42
8522-8529
2003
Homo sapiens
brenda
Niu, X.; Fan, X.; Sun, J.; Ting, P.; Narula, S.; Lundell, D.
Inhibition of fucosyltransferase VII by gallic acid and its derivatives
Arch. Biochem. Biophys.
425
51-57
2004
Homo sapiens (Q11130)
brenda
Sousa, V.L.; Brito, C.; Costa, J.
Deletion of the cytoplasmic domain of human alpha3/4 fucosyltransferase III causes the shift of the enzyme to early Golgi compartments
Biochim. Biophys. Acta
1675
95-104
2004
Mesocricetus auratus
brenda
Stoykova, L.I.; Liu, A.; Scanlin, T.F.; Glick, M.C.
alpha1,3 Fucosyltransferases in cystic fibrosis airway epithelial cells
Biochimie
85
363-367
2003
Homo sapiens
brenda
Palma, A.S.; Morais, V.A.; Coelho, A.V.; Costa, J.
Effect of the manganese ion on human alpha3/4 fucosyltransferase III activity
BioMetals
17
35-43
2004
Homo sapiens
brenda
Norris, A.J.; Whitelegge, J.P.; Strouse, M.J.; Faull, K.F.; Toyokuni, T.
Inhibition kinetics of carba- and C-fucosyl analogues of GDP-fucose against fucosyltransferase V: implication for the reaction mechanism
Bioorg. Med. Chem. Lett.
14
571-573
2004
Homo sapiens
brenda
Chandrasekaran, E.V.; Chawda, R.; Rhodes, J.M.; Locke, R.D.; Piskorz, C.F.; Matta, K.L.
The binding characteristics and utilization of Aleuria aurantia, Lens culinaris and few other lectins in the elucidation of fucosyltransferase activities resembling cloned FT VI and apparently unique to colon cancer cells
Carbohydr. Res.
338
887-901
2003
Homo sapiens (P51993), Homo sapiens (Q11128)
brenda
Abe, H.; Ohba, M.; Shimma, Y.I.; Jigami, Y.
Yeast cells harboring human alpha-1,3-fucosyltransferase at the cell surface engineered using Pir, a cell wall-anchored protein
FEMS Yeast Res.
4
417-425
2004
Homo sapiens
brenda
Dupuy, F.; Germot, A.; Julien, R.; Maftah, A.
Structure/function study of Lewis alpha3- and alpha3/4-fucosyltransferases: the alpha1,4 fucosylation requires an aromatic residue in the acceptor-binding domain
Glycobiology
14
347-356
2004
Homo sapiens (P21217), Homo sapiens (P51993), Homo sapiens (Q11128), Hylobates lar (Q8HYJ3), Pongo pygmaeus (Q8HYJ4), Pongo pygmaeus (Q8HYJ5), Gorilla gorilla (Q8HYJ6), Gorilla gorilla (Q8HYJ7)
brenda
Leonard, R.; Lhernould, S.; Carlue, M.; Fleurat, P.; Maftah, A.; Costa, G.
Biochemical characterization of Silene alba alpha4-fucosyltransferase and Lewis a products
Glycoconj. J.
22
71-78
2005
Silene latifolia subsp. alba
brenda
Ma, B.; Wang, G.; Palcic, M.M.; Hazes, B.; Taylor, D.E.
C-terminal amino acids of Helicobacter pylori alpha1,3/4 fucosyltransferases determine type I and type II transfer
J. Biol. Chem.
278
21893-21900
2003
Helicobacter pylori (Q9L8S4), Helicobacter pylori, Helicobacter pylori NCTC116639 (Q9L8S4), Helicobacter pylori UA948 (Q9L8S4)
brenda
Morais, V.A.; Costa, J.
Stable expression of recombinant human alpha3/4 fucosyltransferase III in Spodoptera frugiperda Sf9 cells
J. Biotechnol.
106
69-75
2003
Homo sapiens
brenda
Guo, P.; Zhang, Y.; Zhang, X.Y.; Chen, H.L.; Wang, H.; Narimatsu, H.
Analysis of lewis antigens on cell surface and alpha1,3 fucosyltransferase subtypes in H7721 human hepatocarcinoma cells
J. Exp. Clin. Cancer Res.
22
135-139
2003
Homo sapiens
brenda
Bengtson, P.; Lundblad, A.; Larson, G.; Pahlsson, P.
Polymorphonuclear leukocytes from individuals carrying the G329A mutation in the alpha 1,3-fucosyltransferase VII gene (FUT7) roll on E- and P-selectins
J. Immunol.
169
3940-3946
2002
Homo sapiens
brenda
Dabrowska, A.; Baczynska, D.; Widerak, K.; Laskowska, A.; Ugorski, M.
Promoter analysis of the human alpha1,3/4-fucosyltransferase gene (FUT III)
Biochim. Biophys. Acta
1731
66-73
2005
Homo sapiens
brenda
Rabbani, S.; Miksa, V.; Wipf, B.; Ernst, B.
Molecular cloning and functional expression of a novel Helicobacter pylori alpha-1,4 fucosyltransferase
Glycobiology
15
1076-1083
2005
Helicobacter pylori (Q6ST35), Helicobacter pylori
brenda
Escrevente, C.; Machado, E.; Brito, C.; Reis, C.A.; Stoeck, A.; Runz, S.; Marme, A.; Altevogt, P.; Costa, J.
Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines
Int. J. Oncol.
29
557-566
2006
Homo sapiens
brenda
Ma, B.; Audette, G.F.; Lin, S.; Palcic, M.M.; Hazes, B.; Taylor, D.E.
Purification, kinetic characterization, and mapping of the minimal catalytic domain and the key polar goups of Helicobacter pylori alpha-(1,3/1,4)-fucosyltransferases
J. Biol. Chem.
281
6385-6394
2006
Helicobacter pylori, Helicobacter pylori UA948
brenda
Khaled, A.; Piotrowska, O.; Dominiak, K.; Auge, C.
Exploring specificity of glycosyltransferases: synthesis of new sugar nucleotide related molecules as putative donor substrates
Carbohydr. Res.
343
167-178
2008
Homo sapiens
brenda
Shetterly, S.; Jost, F.; Watson, S.R.; Knegtel, R.; Macher, B.A.; Holmes, E.H.
Site-specific fucosylation of sialylated polylactosamines by alpha1,3/4-fucosyltransferases-V and -VI is defined by amino acids near the N terminus of the catalytic domain
J. Biol. Chem.
282
24882-24892
2007
Homo sapiens
brenda
Lin, C.H.; Lin, C.W.; Khoo, K.H.
Proteomic identification of specific glycosyltransferases functionally implicated for the biosynthesis of a targeted glyco-epitope
Proteomics
8
475-483
2008
Homo sapiens (P21217), Homo sapiens (P51993)
brenda
Tefsen, B.; van Stijn, C.M.; van den Broek, M.; Kalay, H.; Knol, J.C.; Jimenez, C.R.; van Die, I.
Chemoenzymatic synthesis of multivalent neoglycoconjugates carrying the helminth glycan antigen LDNF
Carbohydr. Res.
344
1501-1507
2009
Homo sapiens
brenda
Fagerberg, D.; Angstroem, J.; Halim, A.; Hultberg, A.; Rakhimova, L.; Hammarstroem, L.; Boren, T.; Teneberg, S.
Novel Leb-like Helicobacter pylori-binding glycosphingolipid created by the expression of human alpha-1,3/4-fucosyltransferase in FVB/N mouse stomach
Glycobiology
19
182-191
2009
Homo sapiens
brenda
Carvalho, A.; Harduin-Lepers, A.; Magalhaes, A.; Machado, E.; Mendes, N.; Costa, L.; Matthiesen, R.; Almeida, R.; Costa, J.; Reis, C.
Differential expression of alpha-2,3-sialyltransferases and alpha-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells
Int. J. Biochem. Cell Biol.
42
80-89
2010
Homo sapiens
brenda
Mollicone, R.; Moore, S.E.; Bovin, N.; Garcia-Rosasco, M.; Candelier, J.J.; Martinez-Duncker, I.; Oriol, R.
Activity, splice variants, conserved peptide motifs, and phylogeny of two new alpha1,3-fucosyltransferase families (FUT10 and FUT11)
J. Biol. Chem.
284
4723-4738
2009
Homo sapiens (Q495W5), Homo sapiens (Q6P4F1)
brenda
Barthel, S.; Wiese, G.; Cho, J.; Opperman, M.; Hays, D.; Siddiqui, J.; Pienta, K.; Furie, B.; Dimitroff, C.
Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking
Proc. Natl. Acad. Sci. USA
106
19491-19496
2009
Homo sapiens
brenda
Guo, Q.; Guo, B.; Wang, Y.; Wu, J.; Jiang, W.; Zhao, S.; Qiao, S.; Wu, Y.
Functional analysis of alpha1,3/4-fucosyltransferase VI in human hepatocellular carcinoma cells
Biochem. Biophys. Res. Commun.
417
311-317
2012
Homo sapiens
brenda
Wang, H.; Morales-Levy, M.; Rose, J.; Mackey, L.C.; Bodary, P.; Eitzman, D.; Homeister, J.W.
alpha(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis
Am. J. Pathol.
182
2082-2093
2013
Mus musculus
brenda
Seelhorst, K.; Piernitzki, T.; Lunau, N.; Meier, C.; Hahn, U.
Synthesis and analysis of potential alpha1,3-fucosyltransferase inhibitors
Bioorg. Med. Chem.
22
6430-6437
2014
Helicobacter pylori, Homo sapiens
brenda
Lunau, N.; Seelhorst, K.; Kahl, S.; Tscherch, K.; Stacke, C.; Rohn, S.; Thiem, J.; Hahn, U.; Meier, C.
Fluorescently labeled substrates for monitoring alpha1,3-fucosyltransferase IX activity
Chemistry
19
17379-17390
2013
Helicobacter pylori, Homo sapiens
brenda
Wan, X.; Sato, H.; Miyaji, H.; McDaniel, J.M.; Wang, Y.; Kaneko, E.; Gibson, B.; Mehta-DSouza, P.; Chen, Y.; Dozmorov, M.; Miller, L.P.; Goodman, J.; Sun, Z.; Xia, L.
Fucosyltransferase VII improves the function of selectin ligands on cord blood hematopoietic stem cells
Glycobiology
23
1184-1191
2013
Mus musculus
brenda
Brazil, J.C.; Liu, R.; Sumagin, R.; Kolegraff, K.N.; Nusrat, A.; Cummings, R.D.; Parkos, C.A.; Louis, N.A.
alpha3/4 Fucosyltransferase 3-dependent synthesis of Sialyl Lewis A on CD44 variant containing exon 6 mediates polymorphonuclear leukocyte detachment from intestinal epithelium during transepithelial migration
J. Immunol.
191
4804-4817
2013
Homo sapiens
brenda
Saeki, K.; Satoh, T.; Yokozeki, H.
alpha(1,3) fucosyltransferases IV and VII are essential for the initial recruitment of basophils in chronic allergic inflammation
J. Invest. Dermatol.
133
2161-2169
2013
Mus musculus
brenda
Huang, V.W.; Lee, C.L.; Lee, Y.L.; Lam, K.K.; Ko, J.K.; Yeung, W.S.; Ho, P.C.; Chiu, P.C.
Sperm fucosyltransferase-5 mediates spermatozoa-oviductal epithelial cell interaction to protect human spermatozoa from oxidative damage
Mol. Hum. Reprod.
21
516-526
2015
Homo sapiens
brenda
Yu, H.; Li, Y.; Wu, Z.; Li, L.; Zeng, J.; Zhao, C.; Wu, Y.; Tasnima, N.; Wang, J.; Liu, H.; Gadi, M.R.; Guan, W.; Wang, P.G.; Chen, X.
Helicobacter pylori alpha1-3/4-fucosyltransferase (Hp3/4FT)-catalyzed one-pot multienzyme (OPME) synthesis of Lewis antigens and human milk fucosides
Chem. Commun. (Camb.)
53
11012-11015
2017
Helicobacter pylori
brenda
Okada, T.; Ihara, H.; Ito, R.; Ikeda, Y.
Molecular cloning and functional expression of Lewis type alpha1,3/alpha1,4-fucosyltransferase cDNAs from Mangifera indica L.
Phytochemistry
144
98-105
2017
Mangifera indica (A0A292GKJ7), Mangifera indica (A0A292GLL9)
brenda